MethylSTAT 是一种含有 Jumonji C 结构域的组蛋白去甲基化酶 (JMJD) 抑制剂的甲酯前药，具有良好的细胞渗透性。在体外试验中，methylSTAT 的游离酸可抑制 JMJD2A、JMJD2C、JMJD2E、PHF8 和 JMJD3，IC50 值分别约为 4.3、3.4、5.9、10 和 43 μM。 MethylSTAT 抑制 JMJD2C 敏感的食管癌细胞系 KYSE150 的生长，GI50 为 5.1 μM，而methylSTAT 的游离酸在高达 100 μM 时不抑制细胞生长。 MethylSTAT 以浓度依赖性方式在多个位点诱导组蛋白高甲基化（KYSE150 细胞中 H3K4me3 和 H3K9me3 的 EC50 = 10.3 和 8.6 μM，MCF-7 细胞中的 EC50 分别为 6.7 和 6.3 μM）。

Methylstat is a methyl ester prodrug of a Jumonji C domain-containing histone demethylase (JMJD) inhibitor that has favorable cell permeability. The free acid of methylstat inhibits JMJD2A, JMJD2C, JMJD2E, PHF8, and JMJD3 with IC50 values of approximately 4.3, 3.4, 5.9, 10, and 43 μM, respectively, in an in vitro assay. Methylstat inhibits growth of the JMJD2C-sensitive esophageal cancer cell line KYSE150 with a GI50 of 5.1 μM, whereas the free acid of methylstat did not inhibit cell growth up to 100 μM. Methylstat induces histone hypermethylation at multiple sites in a concentration-dependent manner (EC50 for H3K4me3 and H3K9me3 = 10.3 and 8.6 μM in KYSE150 cells and 6.7 ad 6.3 μM in MCF-7 cells, respectively).

1310877-95-2

C28H31N3O6

505.571

DMSO:25 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years